R J Barth

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors
    R J Barth
    Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 57:291-5. 1999
  2. ncbi A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival
    Richard J Barth
    Department of Surgery, Section of General Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 16:5548-56. 2010
  3. ncbi Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity
    L A Lambert
    Department of Surgery, Dartmouth Medical School and Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Cancer Res 61:641-6. 2001
  4. ncbi Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens
    L A Lambert
    Department of Surgery, Dartmouth Medical School and Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    J Immunother 24:232-6. 2001
  5. ncbi Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
    J M Pipas
    Section Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Ann Oncol 23:2820-7. 2012
  6. ncbi Dendritic cell infiltration in colon cancer
    T Schwaab
    Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    J Immunother 24:130-7. 2001
  7. ncbi A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins
    G R Gibson
    Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Ann Surg Oncol 8:693-704. 2001
  8. ncbi Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
    J M Pipas
    Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Int J Radiat Oncol Biol Phys 50:1317-22. 2001
  9. ncbi Dendritic cells require maturation via CD40 to generate protective antitumor immunity
    M F Mackey
    Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Immunol 161:2094-8. 1998

Research Grants

  1. MECHANISMS UNDERLYING CD40LS ROLE IN TUMOR IMMUNITY
    Richard Barth; Fiscal Year: 2002
  2. COLORECTAL CANCER: CD40 CELL VACCINE THERAPY
    Richard Barth; Fiscal Year: 2001

Collaborators

Detail Information

Publications9

  1. ncbi Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors
    R J Barth
    Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 57:291-5. 1999
    ..However, whether these same histologic criteria can be used to predict the likelihood that a phyllodes tumor will locally recur after breast conserving therapy remains controversial...
  2. ncbi A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival
    Richard J Barth
    Department of Surgery, Section of General Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 16:5548-56. 2010
    ..To determine whether an autologous dendritic cell (DC) vaccine could induce antitumor immune responses in patients after resection of colorectal cancer metastases and whether these responses could be enhanced by activating DCs with CD40L...
  3. ncbi Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity
    L A Lambert
    Department of Surgery, Dartmouth Medical School and Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Cancer Res 61:641-6. 2001
    ..These results support the use of intranodal immunization as a feasible and effective route of DC vaccine administration...
  4. ncbi Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens
    L A Lambert
    Department of Surgery, Dartmouth Medical School and Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    J Immunother 24:232-6. 2001
    ..Furthermore, tumor lysate pulsed DC vaccines generate more potent antitumor immunity than immunization with irradiated tumor cells plus the classic adjuvant, Corynebacterium parvum...
  5. ncbi Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
    J M Pipas
    Section Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Ann Oncol 23:2820-7. 2012
    ..We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC...
  6. ncbi Dendritic cell infiltration in colon cancer
    T Schwaab
    Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    J Immunother 24:130-7. 2001
    ..01). Patients who had a high proportion of TILs expressing tumor necrosis factor (TNF) had a greater intratumor mature DC density than patients with a low proportion of TNF + TIL (0.54 versus 0.21 CD83+ cells/hpf, p < 0.01)...
  7. ncbi A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins
    G R Gibson
    Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Ann Surg Oncol 8:693-704. 2001
    ....
  8. ncbi Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
    J M Pipas
    Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Int J Radiat Oncol Biol Phys 50:1317-22. 2001
    ..To determine the maximum tolerated dose and dose-limiting toxicity associated with twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas...
  9. ncbi Dendritic cells require maturation via CD40 to generate protective antitumor immunity
    M F Mackey
    Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Immunol 161:2094-8. 1998
    ..These data suggest that impaired antitumor responses in the absence of CD40/CD154 interactions are the result of a lesion in APC function, namely IL-12 production, and that CD40 plays a critical role in the maturation of DCs in vivo...

Research Grants3

  1. MECHANISMS UNDERLYING CD40LS ROLE IN TUMOR IMMUNITY
    Richard Barth; Fiscal Year: 2002
    ..We expect that these studies will form the basis for new immunotherapy clinical trials. ..
  2. COLORECTAL CANCER: CD40 CELL VACCINE THERAPY
    Richard Barth; Fiscal Year: 2001
    ..Induction of systemic immunity to KLH and to tumor cells will be assessed. ..